Spinoff Companies and Affiliates

Roswell Park Cancer Institute is helping to revitalize the region’s economy via the spinoff companies formed by Roswell Cancer Institute employees and utilizing technologies developed here. Committing the infrastructure, intellectual capital and necessary resources to convert its scientific discoveries into products/applications, RPCI has established a number of biotech spinoff companies, and formed strategic partnerships with investigators and centers throughout the world. Examples of biotech spinoff companies are:

Cleveland BioLabs, Inc.

  • Clinical-stage biotechnology company with a focus on oncology and orphan drug development located on the Buffalo Niagara Medical Campus
  • Formed in 2003 by Andrei V. Gudkov, Ph.D., D.Sci., Senior Vice President for Basic Science and Chairman of the Department of Cell Stress Biology
  • Pursuing the research, development and commercialization of proprietary products that have the potential to treat cancer, prevent and treat acute radiation syndrome and counteract the toxic effects of radio and chemotherapies for oncology patients
  • Publicly funded corporation (Nasdaq:CBLI) and has nine product candidates in their pipeline, most notably Entolimod (CBLB502), which is currently in clinical studies
  • These candidates are being developed directly by Cleveland BioLabs and their majority-owned subsidiaries, Incuron, L.L.C. and Panacela Labs, Inc.
  • For more information, visit www.cbiolabs.com

Incuron, L.L.C.

  • Drug development company formed in 2009 by Andrei V. Gudkov, Ph.D., D.Sci., Senior Vice President for Basic Science and Chairman of the Department of Cell Stress Biology
  • Headquartered in Russia
  • Joint venture formed between Cleveland BioLabs and BioProcess Capital Ventures (a Russian investment company) and majority owned by Cleveland BioLabs
  • Actively developing compounds that fight cancer, specifically CBL0137 and CBL0102. CBL0137 is in clinical studies and CBL0102 has been granted orphan drug status.
  • For more information, visit www.incuron.com/en

Panacela Labs, Inc.

  • Drug development company formed in 2011 by Andrei V. Gudkov, Ph.D., D.Sci., Senior Vice President for Basic Science and Chairman of the Department of Cell Stress Biology
  • Headquartered in Buffalo, NY
  • Joint venture founded by Cleveland BioLabs and Rusnano (a Russian investment company) in collaboration with Roswell Park Cancer Institute, Children’s Cancer Institute of Australia and Cleveland Clinic Foundation
  • Focused on developing five product candidates from the laboratory of Dr. Gudkov:
    • Revercom – Chemotherapy sensitizer
    • Mobilan – Adenovirus-based cancer immunotherapy
    • Arkil – Inhibitor of Androgen receptor targeting prostate cancer
    • Antimycon – Inhibitor of MYC oncogene
    • Xenomycins – Anti-bacterial and anti-fungal family of compounds
  • For more information, visit www.panacelalabs.com

Oncotartis, Inc.

  • Drug development company formed in 2011 by Andrei V. Gudkov, Ph.D., D.Sci., Senior Vice President for Basic Science and Chairman of the Department of Cell Stress Biology
  • Headquartered in Buffalo, NY
  • Privately funded and has received funding from BioProcess (a Russian investment company)
  • Actively developing compounds that fight cancer
  • For more information, visit www.tartiscorp.com

Tartis Aging, Inc.

  • Drug development company formed in 2011 by Andrei V. Gudkov, Ph.D., D.Sci., Senior Vice President for Basic Science and Chairman of the Department of Cell Stress Biology
  • Headquartered in Buffalo, NY
  • Privately funded
  • Actively developing compounds that fight the aging process and age related diseases
  • For more information, visit www.tartiscorp.com

Simulated Surgical Systems, L.L.C.

  • Formed in 2009 by Khurshid Guru, M.D., Director of Robotic Surgery at Roswell Park Cancer Institute and Thenkurussi Kesavadas, Ph.D., Director of the University at Buffalo’s Virtual Reality Lab
  • Located in Williamsville, NY
  • Privately funded
  • Manufactures and sells training simulators for the current DaVinci Robotic Surgery System
  • Formed to commercialize the ROSS™ robotic surgery simulator developed jointly by Drs. Guru and Kesavadas at Roswell Park Cancer Institute and the University at Buffalo
    • The ROSS™ robotic surgery simulator is a valuable training tool that provides surgeons hands-on training for robot-assisted surgery
  • For more information, visit www.simulatedsurgicals.com

Empire Genomics, L.L.C.

  • Privately funded molecular diagnostics company formed in 2006 that develops and offers a comprehensive menu of assay services for use in diagnosing and guiding precise therapeutic treatments for patients
  • Located in Buffalo, NY
  • Created by Norma Nowak, Ph.D., Director of the DNA Microarray and Genomics Facility at Roswell Park, to commercialize genomic technology developed at RPCI
  • Offers completely integrated services which are focused on providing diagnostic, prognostic, therapeutic and disease-monitoring information for the oncology market
  • For more information, visit www.empiregenomics.com

AndroBioSys, Inc.

  • Privately funded bio-pharmaceutical company formed in 2006 by James Mohler, M.D., Associate Director and Senior-Vice President for Translational Research, and Gary J. Smith, Ph.D., Distinguished Professor of Urology
  • Headquartered in Buffalo, NY
  • The company is focused on the following:
    • Advanced prostate disease imaging and therapeutics
    • The discovery and development of drugs for the treatment of prostate disease and other hormone-sensitive cancers
    • Contract research for academic, biotechnology and pharmaceutical clients
  • Active in developing targeted therapeutics and preclinical testing assays that will be more predictive of clinical efficacy of cancer therapies
  • Provides proprietary contract research services in the angiogenesis area and has established models that use isolated cancerous human prostate, breast and ovarian cells and tissues
  • For more information, contact infoabs@androbiosys.com or visit www.androbiosys.com

CureFAKtor Pharmaceuticals, L.L.C.

  • Privately funded oncology biopharmaceutical company formed in 2008 by William Cance, M.D., F.A.C.S., Chair of the Department of Surgical Oncology
  • Headquartered in Orchard Park, NY
  • Formed to develop and commercialize advanced proprietary technologies developed by Dr. Cance and his colleagues Elena V. Kurenova, Ph.D., Research Scientist and Associate Professor of Oncology, and Vita M. Golubovskaya, Ph.D., Associate Professor of Oncology, involving inhibition of Focal Adhesion Kinase (FAK)
    • FAK is overexpressed in many solid tumors and is an important facilitator for signaling that causes tumor cells to survive, grow, and produce new blood vessels to sustain growth and travel to distant places within the body where they may establish new tumor sites
  • Has identified more than 40 compounds that target FAK signaling sites, and a lead compound CFAK-C4, has been granted orphan drug status
  • For more information, visit www.curefaktor.com

Photolitec, L.L.C.

  • Photodynamic Therapy (PDT) and imaging technology company formed in 2010 by Ravindra Pandey, Ph.D., Distinguished Member of the Department of Cell Stress Biology
  • Headquartered in East Amherst, NY
  • Privately funded and has received funding from Zhejiang Hisun Pharmaceutical Co. Ltd.
  • Actively engaged in the clinical development and commercialization of advanced proprietary technologies licensed from Roswell Park Cancer Institute and involving photosensitizing compounds used to identify cancer through medical imaging and for treating cancer by applying an appropriate light source to the photosensitized tumors
  • For more information, visit www.photolitec.org

Generate BioMed, Inc.

  • Formed in 2011 by Jeffrey Serbin, M.D., and Michael Rosenman
  • Privately funded Heat-Shock Vaccine discovery and development company formed to commercialize technology developed at Roswell Park Cancer Institute by John Subjeck, Ph.D., and Shawn Wang, Ph.D., both of Cell Stress Biology
  • Headquartered in New York, NY
  • Actively engaged in clinical studies and commercialization of licensed Heat-Shock protein technology (HSP 110) that may help the body form an immune response to antigens on cancer cells, essentially causing the antigens to function as a vaccine
  • Plans to operate as a Heat-Shock Vaccine discovery and development company researching and commercializing technologies linked to Heat-Shock proteins and their functions
  • For more information, contact admin@generatebiomed.com or visit www.generatebiomed.com

MimiVax, L.L.C.

  • Privately funded oncology vaccine development company formed in 2011 by Robert Fenstermaker, M.D., Chair of the Department of Neurosurgery, and Michael J. Ciesielski, Ph.D., Assistant Professor of Neurosurgery
  • Located in Buffalo, NY
  • Formed to develop and commercialize proprietary technology developed by Drs. Fenstermaker and Ciesielski and licensed from Roswell Park Cancer Institute involving oncology vaccines and targeted therapies for cancer treatment
  • The technology is intended to stimulate a strong immune response to the Survivin molecule, an important cellular protein involved in cancer cell metabolism, as a way of fighting cancer
  • Lead agent (MV-01) is in Phase 1 clinical studies
  • For more information, visit www.mimivax.com